Effects of low-dose dapagliflozin on heart failure–related outcomes in patients with heart failure and type 2 diabetes: a subanalysis of the dapper study
The efficacy of sodium–glucose cotransporter 2 inhibitors in heart failure (HF) has been well established. Dapagliflozin 10 mg has been shown to improve clinical outcomes in HF in DAPA-HF and DELIVER; however, evidence supporting low-dose dapagliflozin in HF remains limited. This post hoc analysis of the D...